Remove 2020 Remove Competition Remove Prescription
article thumbnail

PBMs and insurers want your prescription money

World of DTC Marketing

For many, these coupons represent the difference between filling a prescription and going without lifesaving care, but there is a lot more here than just a co-pay coupon. Those health insurers, in turn, use the discounts to offer more competitive premiums in a bid to attract enrollees. These pricing scams hurt patients as well.

Insurance 226
article thumbnail

Pharma’s reputational high will be short-lived

World of DTC Marketing

Pharma has gone to court again and again to delay generic competition of biologic drugs. One company AbbVie has used the courts to stop competition of its top drug Humira. By the look of 2020’s results, he’s on the right track—and his compensation shows it. For writing that 2020 success story, CEO Albert Bourla, Ph.D.,

Pharma 186
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Pharma is “big business” that uses excuses to keep prices high

World of DTC Marketing

Seventy-nine percent of Americans think the price of prescription drugs is “unreasonable,” according to a 2019 Kaiser Family Foundation poll , and about 9 in 10 say they support the idea of the government negotiating prices. For 17 of the 20 top-selling drugs worldwide in 2020, pharmaceutical corporations made more money from U.S.

Pharma 241
article thumbnail

UnitedHealth-Walmart partnership heats up U.S. Medicare provider competition

Clarivate

Insurers that incentivize using Walmart facilities in Medicare Advantage and prescription drug plans (PDPs) have seen success; Humana has a long-running standalone Part D plan with Walmart pharmacies as preferred network locations. Medicare provider competition appeared first on Clarivate. payer marketplace, please visit us here.

article thumbnail

Nine for 2023, part three: thriving or surviving?

pharmaphorum

In this final instalment of IQVIA EMEA Thought Leadership’s Nine for 2023 three-part series, focusing on issues that will change the direction of healthcare and the pharmaceutical industry this year, three key competitive issues for pharmaceutical companies in 2023 are assessed.

article thumbnail

Fentanyl: a horrifyingly disruptive drug

Pharmaceutical Technology

Theft, fraudulent prescriptions and unsanctioned distribution by patients and medical practitioners are the most common ways in which legal fentanyl products are illegally secured. According to the National Institute of Drug Abuse, the total number of drug-involved overdose deaths in the US increased from 52,404 in 2015 to 91,799 in 2020.

Safety 105
article thumbnail

PM360 Q&A with Adrian Adams, Chairman & CEO, Impel Pharmaceuticals

PM360

Most recently, he took over the then-called Impel NeuroPharma in May 2020—at the height of the pandemic—and since then has led the company through its first product approval, undergone an initial public offering (IPO), rebranded to Impel Pharmaceuticals, and attracted big interest from Big Pharma in its novel drug delivery technology.